Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H26N2O2 |
Molar mass | 362.473 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Dexetimide (brand name Tremblex) is a piperidine anticholinergic. It is a muscarinic antagonist that is used to treat drug induced parkinsonism. Dexetimide was discovered at Janssen Pharmaceutica in 1968.
References
- Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- Dom R, Van Lommel R, Baro F (1971). "A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent". Acta Psychiatrica Scandinavica. 47 (4): 399–410. doi:10.1111/j.1600-0447.1971.tb03697.x. PMID 4947805. S2CID 10591790.
- Huygens H, Vereecken JL, Tanghe A (1973). "Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action". Psychiatria, Neurologia, Neurochirurgia. 76 (4): 251–9. PMID 4581374.
Antiparkinson agents (N04) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Dopaminergics |
| ||||||||||
Anticholinergics | |||||||||||
Others |
| ||||||||||
|
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |